We thank Călugăru and Călugăru 1 for their constructive comments regarding our article ‘Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab’. 2 We appreciate ...

SAN FRANCISCO, April 21, 2025 /PRNewswire/ -- Perfuse Therapeutics, Inc. ("Perfuse Therapeutics"), a biopharmaceutical company pioneering transformational therapies to treat ischemia-induced ocular ...

Perfuse Therapeutics has reported 24-week data from its first-in-human, multi-centre Phase I/IIa trial of the PER-001 intravitreal implant for individuals with glaucoma. The trial of PER-001 is ...

Please provide your email address to receive an email when new articles are posted on . One-fifth of patients who received ocular steroid injections were later diagnosed with glaucoma or ocular ...

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class ...

eye surgery Study shows reductions in intraocular pressures and antiglaucoma medication use. Intravitreal bevacizumab administration improves outcomes, and may reduce both intraocular pressure (IOP) ...

Please provide your email address to receive an email when new articles are posted on . NEW YORK — Anterior chamber paracentesis may be an effective option to reduce IOP spikes after intravitreal ...

Patients with retinal vein occlusion-related macular edema had a higher likelihood of blindness and low vision if they had low best-corrected visual acuity after 1 month of intravitreal treatment.

CHICAGO — Topical antibiotic prophylaxis is completely unnecessary in association with intravitreal injections, according to findings from more than 15,000 injections by a single surgeon who presented ...

Seven different postoperative complications occurred two to four times more often in patients who had a history of intravitreal drug injections as compared with those who did not. Among complications ...